Appendix B
Public Meeting Agenda March 11, 2002
Immunization Safety Review Committee
Hepatitis B Vaccine and Neurological Disorders
Foundry Building, Room 2004
Washington, DC
8:30–8:45 am |
Welcome and Introduction Marie McCormick, MD, ScD Committee Chair |
8:45–9:00 am |
Clinical Description and Diagnosis of Multiple Sclerosis Emmanuelle Waubant, MD University of California, San Francisco Multiple Sclerosis Center (co-author of commissioned paper posted on IOM website) |
9:00–9:30 am |
Pharmacovigilance and Case-Control Study of Hepatitis B Vaccine and Multiple Sclerosis Bernard Begaud, MD, PhD (Presented via conference call) Annie Fourrier, PharmD, MPH (Presented via conference call) Universite Victor Segalen Bordeaux, France |
9:30–10:15 am |
Risk of Multiple Sclerosis Relapse After Immunization: European Database for Multiple Sclerosis |
|
Samy Suissa, PhD McGill University |
10:15–10:30 am |
Break |
10:30–11:15 am |
Risk of Multiple Sclerosis After Hepatitis B Immunization: The Nurses’ Health Study Alberto Ascherio, MD, DrPH Harvard University |
11:15 am–12:00 pm |
Risk of Demyelinating Disease After Hepatitis B Vaccination: The Vaccine Safety Datalink Frank DeStefano, MD, MPH Centers for Disease Control and Prevention |
12:00 pm–1:00 pm |
Lunch |
1:00–1:45 pm |
Possible Mechanisms for Hepatitis B Vaccine-Induced Multiple Sclerosis and Other Demyelinating Diseases Emmanuelle Waubant, MD University of California, San Francisco Multiple Sclerosis Center (co-author of commissioned paper posted on IOM website) |
1:45–2:30 pm |
Recommendations for Newborn and Infant Hepatitis B Vaccination Historical Perspective Neal Halsey, MD Johns Hopkins University Recent Analyses of Hepatitis B Viral Infections in Children Eric Mast, MD National Center for Infectious Diseases Centers for Disease Control and Prevention |